Clinical Report: Effectiveness and Safety of PARP Inhibitors in Elderly Patients

Overview

This systematic review and network meta-analysis evaluates the efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer. It highlights increased risks of hematologic toxicities.

Background

Older adults are often underrepresented in clinical trials, leading to a lack of age-specific evidence for treatments like PARP inhibitors in advanced ovarian cancer. Understanding the efficacy and safety of these therapies in this demographic is crucial.

Data Highlights

Key Findings

• PARP inhibitors improved progression-free survival (PFS) in older patients (≥65 years).
• Olaparib, rucaparib, and niraparib showed significant PFS benefits compared to placebo or chemotherapy.
• Niraparib was associated with increased odds of treatment-emergent adverse events.
• Both niraparib and olaparib had higher risks of grade ≥3 anemia and other hematologic toxicities.
• Placebo or chemotherapy ranked most favorably across most safety outcomes.

Clinical Implications

Clinicians should consider the potential benefits of PARP inhibitors for older patients with advanced ovarian cancer while also being vigilant about the increased risk of hematologic toxicities. Individualized treatment plans that account for patient age and comorbidities may be necessary.

Conclusion

PARP inhibitors demonstrate efficacy in improving PFS for older patients with advanced ovarian cancer, but their safety profiles warrant careful consideration.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study
2. The ASCO Post, 2025 -- Advanced Epithelial Ovarian Cancer: First-Line PARP Inhibitor Maintenance Therapy and Survival
3. Frontiers in Oncology, 2026 -- Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability
4. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer - PMC, 2025
5. JAMA Network Open, 2025 -- PARP Inhibitor After Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer
6. The ASCO Post — Expert Point of View: Novel Agents Prolong Disease-free Survival in Ovarian Cancer
7. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer - PMC
8. PARP Inhibitor After Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer
9. Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy | International Journal of Clinical Oncology | Springer Nature Link